Human ORC/MCM density is low in active genes and correlates with replication time but does not delimit initiation zones
- Helmholtz Zentrum München (GmbH), Germany
- INSERM, France
- Gene Center, LMU Munich, Germany
- Helmholtz Zentrum Munich, Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH), Germany
- Deutsches Zentrum für Neurodegenerative Erkrankungen, Germany
- Helmholtz Zentrum München (GmbH), German Research Center for Environmental Health and German Center for Infection Research (DZIF), Germany
- Inserm, France
- Institut de Biologie de l'Ecole Normale Supérieure, France
- CNRS, Ecole Normale Supérieure de Lyon, France
Abstract
Eukaryotic DNA replication initiates during S phase from origins that have been licensed in the preceding G1 phase. Here, we compare ChIP-seq profiles of the licensing factors Orc2, Orc3, Mcm3, and Mcm7 with gene expression, replication timing and fork directionality profiles obtained by RNA-seq, Repli-seq and OK-seq. ORC and MCM are significantly and homogeneously depleted from transcribed genes, enriched at gene promoters, and more abundant in early- than in late-replicating domains. Surprisingly, after controlling these variables, no difference in ORC/MCM density is detected between initiation zones, termination zones, unidirectionally replicating and randomly replicating regions. Therefore, ORC/MCM density correlates with replication timing but does not solely regulate the probability of replication initiation. Interestingly, H4K20me3, a histone modification proposed to facilitate late origin licensing, was enriched in late replicating initiation zones and gene deserts of stochastic replication fork direction. We discuss potential mechanisms specifying when and where replication initiates in human cells.
Data availability
Sequencing data have been deposited ad the ENA European Nucleotide Archive and NCBI Gene Expression Omnibus as indicatedChIP-Seq: PRJEB32855, RNA-seq Raji: PRJEB31867 OK-seq Raji: PRJEB25180, Repli-seq Raji: GSE102522, OK-seq mESC: SRR,7535256, OK-seq mouse B-cells: GSE116319All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-6; Fig. 1-Fig.1-Suppl. 3; Fig2-Fig2 Suppl. 1,2; Fig3-Fig3-Suppl. 1; Fig. 4-Fig.4 Suppl. 1,2; Fig5-Fig.5-Suppl. 1; Fig7-Fig.7-Suppl. 1
-
Human ORC/MCM density is low in active genes and correlates with replication time but does not delimit initiation zonesENA European Nucleotide Archive, PRJEB32855.
-
RNA-seq in Raji cells with inducible BZLF1 prior to and after induction of EBV's lytic cycle by doxycyclineENA European Nucleotide Archive, PRJEB31867.
-
MCM2 promotes symmetric inheritance of modified histones during DNA replicationENA European Nucleotide Archive, SRR7535256.
-
OK-seq profile from cycling (S) phase untreated B cellsNCBI Gene Expression Omnibus, GSE116319.
Article and author information
Author details
Wolfgang Hammerschmidt
Funding
Helmholtz Zentrum Muenchen
- Nina Kirstein
- Alexander Buschle
- Wolfgang Hammerschmidt
- Aloys Schepers
National Cancer Institute (CA70723)
- Wolfgang Hammerschmidt
Deutsche Forschungsgemeinschaft (SFB 1064 TP05; SFB1064/TP A13,SFB-TR36/TP A04)
- Wolfgang Hammerschmidt
- Aloys Schepers
Agence Nationale de la Recherche (ANR-15-CE12-0011,ANR-18-CE45-0002,ANR-19-CE12-0028,ANR-10-IDEX-0001-02)
- Olivier Hyrien
- Benjamin Audit
Fondation pour la Recherche Médicale (FRM DEI201512344404)
- Olivier Hyrien
- Benjamin Audit
Canceropole Ile-de-France (PL-BIO16-302)
- Olivier Hyrien
- Benjamin Audit
INCa
- Olivier Hyrien
Ligue Nationale Contre le Cancer (RS19/75-75)
- Olivier Hyrien
Association pour la Recherche sur le Cancer (PJA 20171206387)
- Olivier Hyrien
Deutsche Krebshilfe (70112875)
- Wolfgang Hammerschmidt
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2021, Kirstein et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,392
- views
-
- 378
- downloads
-
- 28
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Human ORC/MCM density is low in active genes and correlates with replication time but does not delimit initiation zones
eLife 10:e62161.
https://doi.org/10.7554/eLife.62161
Further reading
-
- Cancer Biology
- Chromosomes and Gene Expression
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.
-
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.
